Aether Industries Ltd

- For FY27, Aether Industries expects additional debt of approximately INR 200-250 crores due to ongoing investments and working capital needs. - The company acknowledges that debt will increase gradually and sequentially as capex progresses, not in a lump sum. - Recent QIP equity fundraising was completed in Q3 FY26, reducing immediate reliance on equity. - Total remaining capex across sites is estimated at INR 1,500-1,600 crores over the next 4 years, suggesting need for continued capital raising, likely through debt. - No explicit mention of immediate planned equity fundraising after the QIP in Q3 FY26. - The company is focusing on disciplined execution and operating cash flow management alongside raising funds for growth.

- FY26 capex was INR 383.8 crores; FY27 capex expected between INR 300-350 crores, primarily for Site 5 and new R&D site. - Total remaining capex across announced 3 sites is approximately INR 1500-1600 crores over the next 4 years. - Major capex focus: Site 5 commercialization and expansion, Site 1 R&D expansion. - Site 5 planned for up to 20 production blocks over ~45-46 acres including newly acquired adjoining land. - Investment in expanded world-class R&D infrastructure including large pilot plants and 18 new fume hoods. - Site 5’s asset turn target is 1.5 to 1.75. - Capex and R&D investments aimed to drive transition to 70% revenue from CRAMS and CEM models by FY30. - Additional debt of INR 200-250 crores expected in FY27 to support capex. - Expansion of senior leadership team focused on technology and business development to capitalize on opportunities.

- Targeting 70% revenue from CRAMS and CEM and around 30% from Large Scale Manufacturing (LSM) in the next couple of years. - Major growth drivers in FY27 include commercialization of Site 5 Phase 1 and ramp-up of Site 3++ and Site 4. - Expect sustained elevated prices in LSM for next 2-3 quarters, supporting stable/strong revenues. - Site 5 to commercialize three new LSM products priced at $30-$40/kg, expected to contribute meaningfully from FY27. - Anticipate revenue growth from existing marquee customers like Milliken and Baker Hughes, supplemented by new projects and sites. - Working capital improvements expected, with days reduced toward ~160 by FY27 end, supporting operational efficiency. - Capex of INR1,500-1,600 crore over next 4 years focused on expanding manufacturing and R&D capabilities for sustained growth. - No explicit revenue growth guidance given, but accelerating adoption of new chemistries and production blocks indicates positive volume momentum.

- Revenue growth expected from commercialization and ramp-up of Site 5, Site 3++, and Site 4, with strong contributions from CEM and CRAMS segments. - Targeting stable EBITDA margins between 29% to 30% and PAT margins around 19% to 20% for FY27. - CRAMS and CEM expected to contribute approximately 70% of revenue over next 3-4 years, with LSM around 30%. - EBITDA grew 53% YoY in FY26; PAT up 39% YoY, showcasing improving profitability. - Sustainable medium-term pricing environment expected, particularly in LSM business, supporting margins. - Capex of INR1,500-1,600 crores over next 4 years aimed at expansion, with asset turns at Site 5 targeted between 1.5 to 1.75. - Working capital improvements targeted, aiming for reduction from 179 to around 160 days by FY27, supporting cash flows. - Management refrains from explicit EPS guidance but emphasizes accelerated growth supported by new product launches and operational scale-up.

- The transcript does not explicitly mention the exact value or volume of the current or expected order book or pending orders. - It highlights strong order inflows with a focus on new large-scale manufacturing products at Site 5, with validation batches done and orders already in hand for 3 new products expected by May end or early June. - The company has completed over 50 customer and certification audits and added 19 new marquee clients recently. - Multiple customers have completed pre-audits for Site 5, indicating strong customer qualification activity and future order potential. - The focus is on converting opportunities into execution with a growing customer base and expanding capacity at multiple sites. - Continuous order inflows from key customers such as Baker Hughes confirmed, with steady demand and no cancellations or delays mentioned. - Overall, order momentum is strong with increasing mix from CRAMS and CEM contributing to anticipated growth.